These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31737895)

  • 21. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peripheral-T-cell lymphoma with hemophagocytic histiocytosis localised to the bone marrow associated with inappropriate secretion of antidiuretic hormone.
    Ciaudo M; Chauvenet L; Audouin J; Rossert J; Favier R; Horellou MH; Bernadou A; Samama M
    Leuk Lymphoma; 1995 Nov; 19(5-6):511-4. PubMed ID: 8590855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemophagocytic syndrome occurred in a patient with subcutaneous panniculitis-like T-cell lymphoma without overt skin lesion: successful treatment with steroid pulse therapy.
    Miura T; Kawakami Y; Sato M; Ohtsuka M; Yamamoto T
    J Dermatol; 2011 Nov; 38(11):1113-1115. PubMed ID: 21545491
    [No Abstract]   [Full Text] [Related]  

  • 24. Optimizing chemotherapeutic strategies for peripheral T-cell lymphomas.
    Rosenstein LJ; Link BK
    Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S180-6. PubMed ID: 19073525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
    Hui J; Przespo E; Elefante A
    J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.
    Jia B; Hu S; Yang J; Zhou S; Liu P; Qin Y; Gui L; Yang S; Lin H; Zhang C; Xing P; Wang L; Dong M; Zhou L; Sun Y; He X; Shi Y
    Hematology; 2016 Oct; 21(9):536-41. PubMed ID: 27077778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gemcitabine combined with cisplatin and methylprednisolone sodium succinate in chemotherapy for relapsed or refractory T cell non-Hodgkin lymphoma].
    Zhao S; Zhang QY; Sun WZ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):316. PubMed ID: 20510089
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
    Yamaguchi M; Kotani T; Nakamura Y; Ueda M
    Int J Hematol; 2006 Jun; 83(5):450-3. PubMed ID: 16787878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate.
    Leitenberger JJ; Berthelot CN; Polder KD; Pro B; McLaughlin P; Jones D; Duvic M
    J Am Acad Dermatol; 2008 Mar; 58(3):480-4. PubMed ID: 18280345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.
    Arkenau HT; Chong G; Cunningham D; Watkins D; Sirohi B; Chau I; Wotherspoon A; Norman A; Horwich A; Matutes E
    Haematologica; 2007 Feb; 92(2):271-2. PubMed ID: 17296587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel agents in development for peripheral T-cell lymphoma.
    O'Connor OA
    Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
    Shimanovsky A; Dasanu CA
    Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Doxorubicin and etoposide-besed combination chemotherapy regimen for peripheral T-cell lymphoma].
    Zheng W; Zhu J; Xie Y
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):875-6. PubMed ID: 19173838
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined methotrexate and prednisone.
    Gerlando Q; Barbera V; Ammatuna E; Franco V; Florena AM; Mariani G
    Haematologica; 2000 Aug; 85(8):880-1. PubMed ID: 10942945
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
    Otrock ZK; Hatoum HA; Salem ZM; Tawil A; Mahfouz RA; Zaatari GS; Bazarbachi A
    Ann Hematol; 2008 Dec; 87(12):1023-4. PubMed ID: 18587577
    [No Abstract]   [Full Text] [Related]  

  • 37. Subcutaneous panniculitis-like T-cell lymphoma in a patient with long-term remission with standard chemotherapy.
    Zhang H; Gupta R; Wang JC; Lipton JF; Huang YW
    J Natl Med Assoc; 2007 Oct; 99(10):1190-2. PubMed ID: 17987923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
    Lee SS; Jung SH; Ahn JS; Kim YK; Cho MS; Jung SY; Lee JJ; Kim HJ; Yang DH
    J Korean Med Sci; 2016 Jul; 31(7):1160-3. PubMed ID: 27366017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pleomorphic T-cell lymphoma. The diagnostic problems, therapeutic possibilities and infection-induced complications].
    Lob S; Bergmann L; Müller H; Jacobi V; Hoelzer D
    Dtsch Med Wochenschr; 1993 May; 118(21):780-4. PubMed ID: 7684964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
    Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.